• (PLX AI) – Lundbeck shares rose 4% in morning trading after Nordea reiterated a buy recommendation on the stock, saying it was undervalued.
  • • Price target raised to DKK 271 from DKK 265
  • • Lundbeck has prospects for significant sales acceleration on Vyepti for migraines, Nordea said
  • • Vyepti is positioned to win in the long term, and the stock is at substantial discount valuation to the sector, analysts at Bank of America said
  • • However, near-term growth is heavily predicated on Vyepti, accounting for 65% of Lundbeck's consensus growth, and with questions whether this can be achieved, BofA said, reiterating a neutral recommendation, but lifting the price target to DKK 185 from DKK 170

Quelle: PLX AI